Page 126 - Haematologica March 2020

Ferrata Storti Foundation
Haematologica 2020 Volume 105(3):640-651
Myelodysplastic Syndrome
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
Marlijn Hoeks,1,2 Ge Yu,3 Saskia Langemeijer,4 Simon Crouch,3
Louise de Swart,4 Pierre Fenaux,5 Argiris Symeonidis,6 Jaroslav Čermák,7 Eva Hellström-Lindberg,8 Guillermo Sanz,9 Reinhard Stauder,10
Mette Skov Holm,11 Moshe Mittelman,12 Krzysztof Mądry,13 Luca Malcovati,14 Aurelia Tatic,15 Antonio Medina Almeida,16 Ulrich Germing,17
Aleksandar Savic,18 Njetočka Gredelj Šimec,19 Dominic Culligan,20
Raphael Itzykson,5 Agnes Guerci-Bresler,21 Borhane Slama,22
Arjan van de Loosdrecht,23 Corine van Marrewijk,4 Jackie Droste,4
Nicole Blijlevens,4 Marian van Kraaij,24 David Bowen,25 Theo de Witte26 and Alex Smith3 on behalf of the EUMDS Registry Participants
1Centre for Clinical Transfusion Research, Sanquin Research, Leiden, the Netherlands; 2Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
the Netherlands; 3Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, USA; 4Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands; 5Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France; 6Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece; 7Department of Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha, Czech Republic; 8Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden; 9Department of Haematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain; 10Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria; 11Department of Haematology, Aarhus University Hospital, Aarhus, Denmark; 12Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel; 13Department of Haematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa, Poland; 14Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carettere Scientifico, Policlinico San Matteo, University of Pavia, Pavia, Italy; 15Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania; 16Department of Hematology, Hospital da Luz, Lisbon, Portugal; 17Department of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany; 18Clinic of Hematology - Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; 19Department of Internal Medicine, Division of Hematology, Merkur University Hospital, Zagreb, Croatia; 20Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK; 21Service d'Hématologie, Centre Hospitalier Universitaire Brabois Vandoeuvre, Nancy, France; 22Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon, France; 23Department of Hematology – Cancer Center Amsterdam VU University Medical Center, Amsterdam, the Netherlands; 24Unit Transfusion Medicine, Sanquin Blood Bank, Amsterdam, the Netherlands; 25St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK and 26Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
ABSTRACT
Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data are limited. The aim of this study was to assess the effect of ICT on overall survival and hematologic improvement in lower-risk MDS patients in the European MDS registry. We compared chelated patients with a contemporary, non-chelated control group within the European MDS registry, that met the eligibility criteria for starting iron chelation. A Cox proportional hazards model was used to assess overall survival (OS), treating receipt of chelation as a time-varying variable. Additionally, chelated and non-chelated patients were compared
Correspondence:
THEO DE WITTE
t.dewitte@ncmls.ru.nl
Received: November 19, 2018. Accepted: July 4, 2019. Pre-published: July 5, 2019.
doi:10.3324/haematol.2018.212332
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/105/3/640
©2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
640
haematologica | 2020; 105(3)
ARTICLE